ReiThera is an Italian biotechnology company specialising in the development, manufacture, and commercialisation of viral-based biotherapeutics, including vaccines and gene therapies. With state-of-the-art facilities and decades of experience, ReiThera supports pharmaceutical and biotech companies worldwide by delivering cutting-edge solutions for infectious diseases and advanced therapeutic platforms.

Founded with a mission to harness the potential of viral vectors, ReiThera has established itself as a trusted partner in the pharmaceutical sector. Its expertise spans the entire product lifecycle, from early-stage development through to GMP manufacturing and commercial readiness. Operating from its facilities near Rome, the company is equipped with advanced technology and scalable infrastructure to meet diverse project needs, offering end-to-end support for viral vector-based therapies.

Key Products and Services

Vaccine Development: Expertise in designing and producing vaccines for infectious diseases, using advanced viral vector platforms.
Gene Therapy Manufacturing: End-to-end solutions for the development and production of gene therapies, leveraging proprietary viral platforms.
GMP Manufacturing: High-quality GMP production facilities for clinical and commercial manufacturing of viral-based products.
Customised CDMO Services: Tailored Contract Development and Manufacturing Organisation (CDMO) support, including process development, scale-up, and regulatory compliance.
Platform Technologies: Proprietary viral vector systems optimised for safety, efficacy, and scalability.

ReiThera is committed to innovation and collaboration, continuously pushing the boundaries of viral-based biotherapeutics to meet the growing global demand for advanced treatments. With its robust expertise, proven track record, and client-centric approach, ReiThera is a trusted partner for organisations seeking to deliver transformative therapies that improve patient outcomes worldwide.